The promise of next-generation protein sequencing
About the session
Although decoding the human genome through the invention of DNA sequencing has ushered in a new era of biomedical sciences, this blueprint is not enough. We are defined by more than our genes: to understand the human body, we must understand the proteins that actually perform our day-to-day functions--and malfunctions. Glyphic Biotechnologies is decoding the human proteome through full coverage, de novo protein sequencing at single molecule resolutions, advancing beyond the decades old technologies based on mass spectrometry and ELISAs. This platform will enable the development of novel therapeutics and diagnostics and, ultimately, a deeper understanding of human biology.
Josh is the co-founder and CEO of Glyphic Biotechnologies, a VC-funded biotechnology startup commercializing a next-generation protein sequencing platform. His first-author, peer-reviewed publications have been published in top-tier journals such as Nature Reviews Genetics and Science Translational Medicine. He is also an inventor on 6 issued/filed patents and author on 18 research articles. He was named to the Forbes 30 Under 30 Healthcare list and awarded a Biocom California Catalyst Award in 2021. In his free time, he enjoys going to farmer's markets on Sunday mornings, sipping on dirty chai lattes, and creating pastries from scratch.